Synthetic Cannabinoid Receptor Agonists

Novel Psychoactive Substances: Classification, Pharmacology and Toxicology

Volumn , Issue , 2013, Pages 317-343

  Auwärter, Volker ^a   Dargan, Paul I ^b   Wood, David M ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis; K2; Spice; Synthetic cannabinoid receptor agonists

Indexed keywords

EID: 84903812087     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415816-0.00013-4     Document Type: Chapter

References (149)

1. Mechoulam R, Gaoni.Y A total synthesis of Dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965, 87:3273-3275.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
3. Munro S, Thomas KL, Abu-Shaar M Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
4. Croxford JL Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003, 17(3):179-202.
5. Porter AC, Felder CC The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001, 90(1):45-60.
6. Thakur GA, Tichkule R, Bajaj S, Makriyannis A, et al. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 2009, 19(12):1647-1673.
7. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370(9600):1706-1713.
8. EMCDDA. Understanding the 'spice' phenomenon. EMCDDA. Thematic Papers; 2009.
9. Auwärter V, Kristensen PK, Bartels EM, Bliddal H, Astrup A, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009, 44(5):832-837.
10. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y, et al. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 2009, 57(4):439-441.
11. Dresen S, Ferreiros N, Pütz M, Westphal F, Zimmermann R, Auwärter V, et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010, 45(10):1186-1194.
12. Lindigkeit R, Boehme A, Eiserloh I, et al. Spice: a never ending story?. Forensic Sci Int 2009, 191(1-3):58-63.
13. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y, et al. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010, 198(1-3):31-38.
14. Nakajima J, Takahashi M, Seto T, et al. Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl) methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 2011, 29(2):95-110.
15. Nakajima J, Takahashi M, Seto T, et al. Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase (3'-(aminocarbonyl)(1,1'-biphenyl)-3-yl)-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area. Forensic Toxicol 2013, 31:76-85.
16. Schmidt MM, Sharma A, Schifano F, Feinmann C 'Legal highs' on the net-Evaluation of UK-based websites, products and product information. Forensic Sci Int 2011, 206(1-3):92-97.
17. Vardakou I, Pistos C, Spiliopoulou C Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197(3):157-162.
18. Rosenbaum CD, Carreiro S, Babu KM Here today, gone tomorrow ... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012, 8(1):15-32.
19. Piggee C Investigating a not-so-natural high. Anal Chem 2009, 81(9):3205-3207.
20. Ginsburg BC, McMahon LR, Sanchez JJ, Javors MA Purity of synthetic cannabinoids sold online for recreational use. J Anal Toxicol 2012, 36(1):66-68.
21. Kneisel S, Auwärter V Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 2012, 47(7):825-835.
22. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y, et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 2013, 31:44-53.
23. de Jager AD, Warner JV, Henman M, Ferguson W, Hall A LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine - An Australian perspective. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 897:22-31.
24. Nakajima J, Takahashi M, Seto T, et al. Identification and quantitation of two new naphthoylindole drugs-of-abuse,(1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl) methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalen-1-yl) methanone, with other synthetic cannabinoids in unregulated 'herbal' products circulated in the Tokyo area. Forensic Toxicol 2012, 30(1):33-44.
25. Dargan PI, Hudson S, Ramsey J, et al. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int J Drug Policy 2011, 22(4):274-277.
26. ACMD, Consideration of the major cannabinoid agonists. 2009.
27. Howlett AC, Barth F, Bonner TI, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54(2):161-202.
28. Thakur GA, Nikas S, Makriyannis A CB1 cannabinoid receptor ligands. Mini Rev Med Chem 2005, 5(7):631-640.
29. UNODC. Synthetic cannabinoids in herbal products. SCITEC/24: <>; 2011. http://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf.
30. Baker RR Temperature distribution inside a burning cigarette. Nature 1974, 247:405-406.
31. Gardin A, Kucher K, Kiese B, Appel-Dingemanse S Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos 2009, 37(4):827-833.
32. Zuurman L, Passier PC, de Kam MI, Kleijn HJ, Cohen AF, van Gerven JM Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 2009, 23(6):633-644.
33. Martin BR, Wiley JL, Beletskaya I, et al. Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 2006, 318(3):1230-1239.
34. Bell MR, D'Ambra TE, Kumar V, et al. Antinociceptive (aminoalkyl)indoles. J Med Chem 1991, 34(3):1099-1110.
35. Huffman JW, Zengin G, Wu M-J, et al. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 2005, 13(1):89-112.
36. Shevyrin V, Melkozerov V, Nevero A, et al. Identification and analytical properties of new synthetic cannabimimetics bearing 2,2,3,3-tetramethylcyclopropanecarbonyl moiety. Forensic Sci Int 2012, 226(1-3):62-73.
37. Kavanagh P, Grigoryev A, Savchuk S, Mikhura I, Formanovsky A UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal 2013, (Epub ahead of print).
38. Donohue KM, Steiner RR JWH-018 and JWH-022 as combustion products of AM2201. Microgram J 2012, 9(2):52-56.
39. Choi H, Heo S, Kim E, Hwang BY, Lee C, Lee J Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicol 2013, 31:86-92.
40. Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl) indole in a research chemical and several herbal mixtures. Forensic Toxicol 2012, 30:126-134.
41. Kikuchi H, Uchiyama N, Ogata J, Kikura-Hanajiri R, Goda Y Chemical constituents and DNA sequence analysis of a psychotropic herbal product. Forensic Toxicol 2010, 28(2):77-83.
42. Ogata J, Uchiyama N, Kikura-Hanajiri R, Goda Y DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic Sci Int 2012, (Epub ahead of print).
43. Seely KA, Lapoint J, Moran JH, Fattore L Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39(2):234-243.
44. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108(3):534-544.
45. Teske J, Weller JP, Fieguth A, Rothämel T, Schulz Y, Tröger HD Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(27):2659-2663.
46. Grigoryev A, Kavanagh, Melnik A The detection of the urinary metabolites of 1-((5-fluoropentyl)-1H-indol-3-yl)-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 2013, 5(2):110-115.
47. Grigoryev A, Kavanagh, Melnik A The detection of the urinary metabolites of 3-((adamantan-1-yl)carbonyl)-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 2012, 4(6):519-524.
48. Gershkovich, Hoffman A Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 2007, 32(1):24-32.
49. Winstock AR, Barratt MJ Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013, (Epub ahead of print).
50. Huestis MA Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005, 168:657-690.
51. Kneisel S, Teske J, Auwärter V Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. Drug Test Anal 2013.
52. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol 2008, 32(7):470-477.
53. Skopp G, Potsch L Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol 2008, 32(2):160-164.
54. Karschner EL, Schwilke EW, Lowe RH, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction 2009, 104(12):2041-2048.
55. Zhang Q, Ma P, Cole RB, Wang G, et al. Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal Bioanal Chem 2006, 386(5):1345-1355.
56. Grigoryev A, Savchuk S, Melnik A, et al. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879(15-16):1126-1136.
57. Wintermeyer A, Möller I, Thevis M, et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 2010, 398(5):2141-2153.
58. Sobolevsky T, Prasolov I, Rodchenkov G Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010, 200(1-3):141-147.
59. Sobolevsky T, Prasolov I, Rodchenkov G Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 2012, (Epub ahead of print).
60. Chimalakonda KC, Seely KA, Bratton SM, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012, 40(11):2174-2184.
61. Kavanagh P, Grigoryev A, Melnik A, Simonov A The Identification of the Urinary Metabolites of 3-(4-Methoxybenzoyl)-1-Pentylindole (RCS-4), a Novel Cannabimimetic, by Gas Chromatography-Mass Spectrometry. J Anal Toxicol 2012, 36(5):303-311.
62. Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879(25):2519-2526.
63. Hutter M, Broecker S, Kneisel S, Auwärter V Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J Mass Spectrom 2012, 47(1):54-65.
64. Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 2013, (Epub ahead of print).
65. Howlett AC Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 1984, 35(17):1803-1810.
66. Howlett AC, Fleming RM Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984, 26(3):532-538.
67. Caulfield M, Brown DA Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992, 106(2):231-232.
68. Mackie K, Hille B Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992, 89(9):3825-3829.
69. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
70. Johnson DE, Heald SL, Dally RD, Janis RA Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids 1993, 48(6):429-437.
71. Mechoulam R, Ben-Shabat S, Hanus L Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50(1):83-90.
72. Mascia MS, Obinu MC, Ledent C, et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 1999, 383(3):R1-R2.
73. Ishac EJ, Jiang L, Lake KD, et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996, 118(8):2023-2028.
74. Kathmann M Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 1999, 359(6):466-470.
75. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000, 361(1):19-24.
76. Shen M, Piser TM, Seybold VS, Thayer SA Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996, 16(14):4322-4334.
77. Szabo B, Müller T, Koch H Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 1999, 73(3):1084-1089.
78. Atwood BK, Huffman J, Straiker A, Mackie K, et al. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabino id CB receptor agonist. Br J Pharmacol 2010, 160(3):585-593.
79. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48(3):443-450.
80. Lambert DM, Di Marzo V The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr Med Chem 1999, 6(8):757-773.
81. Wiley JL, Martin BR Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 2002, 121(1-2):57-63.
82. Dziadulewicz EK, Bevan SJ, Brain CT, et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007, 50(16):3851-3856.
83. Aung MM, Griffin G, Huffman JW, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 2000, 60(2):133-140.
84. Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993, 265(1):218-226.
85. D'Ambra TE, Estep KG, Bell MR, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992, 35(1):124-135.
86. Deng H, Gifford AN, Zvonok AM, et al. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 2005, 48(20):6386-6392.
87. Frost JM, Dart MJ, Tietje KR Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 2010, 53(1):295-315.
88. Huffman JW, Mabon R, Wu MJ, et al. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 2003, 11(4):539-549.
89. Huffman JW, Padgett LW Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 2005, 12(12):1395-1411.
90. Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett 2006, 16(20):5432-5435.
91. Huffman JW, Szklennik PV, Almond A, et al. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 2005, 15(18):4110-4113.
92. Makriyannis A, Deng H. Cannabimimetic indole derivatives, W.I. Organization, Editor. 2001.
93. Showalter VM, Compton DR, Martin BR, Abood ME Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996, 278(3):989-999.
94. 3S binding assays. Forensic Toxicol 2011, 29(2):132-141.
95. Paronis CA, Nikas SP, Shukla VG, Makriyannis A Delta(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 2012, 23(8):802-805.
96. Forrester MB, Kleinschmidt K, Schwarz E, Young A Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 2011, 30(4):351-358.
97. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012, 60(4):435-438.
98. Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, et al. Spicy seizure. Am J Med Sci 2012, 344(1):67-68.
99. Schneir AB, Baumbacher T Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012, 8(1):62-64.
100. Cone EJ, Huestis MA Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 1993, 15(6):527-532.
101. Brents LK, Reichard EE, Zimmerman SM, et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011, 6(7):e21917.
102. Brents LK, Gallus-Zawada A, Radominska-Pandya A, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 2012, 83(7):952-961.
103. Seely KA, Brents LK, Radominska-Pandya A, et al. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol 2012, 25(4):825-827.
104. Smith K, Flatley J, Drug misuse declared: findings from the 2010/11 British Crime Survey Home Office Statistical Bulletin 2011.
105. Blunt D. Drug misuse declared: findings from the 2011/12 crime survey for England and Wales 2nd ed. 2012.
106. Pabst A, Piontek D, Kraus L, Müller S Substance use and substance use disorders results of the 2009 epidemiological survey of substance abuse. Sucht 2010, 56(5):327-336.
107. Dick D, Torrance C MixMag drugs survey. MixMag 2010, 225:44-53.
108. Winstock A The 2011 drugs survey. MixMag 2011, 238:50-59.
109. Winstock A MixMag/Global drugs survey. MixMag 2012, 251:68-73.
110. UNODC, World drug report 2012. United Nations publication, Sales No. E.12.XI.1, 2012.
111. Hu X, Primack BA, Barnett TE, Cook RL, et al. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 2011, 6:16.
112. Heltsley R, Shelby MK, Crouch DJ, et al. Prevalence of synthetic cannabinoids in U.S. athletes: initial findings. J Anal Toxicol 2012, 36(8):588-593.
113. Castellanos D, Singh S, Thornton G, Avila M, Moreno A Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011, 49(4):347-349.
114. Monitoring the future: a continuing study of American youth. Available: <> [accessed: 17.04.13]. http://monitoringthefuture.org/.
115. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE Monitoring the Future national survey results on drug use, 1975-2011: Volume I, Secondary school students 2012, Institute for Social Research, The University of Michigan, Ann Arbor.
116. Werse B, Müller O, Schell C, Morgenstern C. Annual report 'MoSyD'. Drug trends in Frankfurt am Main 2010. Goethe-University Frankfurt am Main, Centre for Drug Research. 2011.
117. Berry-Caban CS, Kleinschmidt PE, Rao DS, Jenkins J Synthetic cannabinoid and cathinone use among US soldiers. US Army Med Dep J 2012, 19-24.
118. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE Monitoring the Future national results on drug use: 2012 overview, key findings on adolescent drug use 2013, Institute for Social Research, The University of Michigan, Ann Arbor.
119. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE Monitoring the Future national survey results on drug use, 1975-2011: Volume II, College students and adults ages 19-50 2012, Institute for Social Research, The University of Michigan, Ann Arbor.
120. Wood DM, Hunter L, Measham F, Dargan PI Limited use of novel psychoactive substances in South London nightclubs. QJM 2012, 105(10):959-964.
121. Werse B, Morgenstern C. Final report-online-survey on 'Legal Highs' (German). Goethe-University Frankfurt am Main, Centre for Drug Research. 2011.
122. Barratt MJ, Cakic V, Lenton S Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013, 32(2):141-146.
123. Tomiyama K, Funada M Cytotoxicity of synthetic cannabinoids found in "Spice" products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol Lett 2011, 207(1):12-17.
124. Koller VJ, Zlabinger GJ, Auwärter V, Fuchs S, Knasmueller S Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB. Arch Toxicol 2013, (Epub ahead of print).
125. Wood DM, Dargan I Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 2012, 34(4):363-367.
126. Vandrey R, Dunn KE, Fry JA, Girling ER A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012, 120(1-3):238-241.
127. ACMD. Further consideration of the synthetic cannabinoids. 2012.
128. Every-Palmer S Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010, 105(10):1859-1860.
129. Every-Palmer S Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011, 117(2-3):152-157.
130. Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010, 118(1-3):309-310.
131. Müller H, Huttner HB, Köhrmann M, Wielopolski JE, Kornhuber J, Sperling W Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 2010, 43(4):152-153.
132. Tung CK, Chiang T, Lam M Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 2012, 22(1):31-33.
133. Vearrier D, Osterhoudt KC A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 2010, 26(6):462-465.
134. Simmons J, Cookman L, Kang C, Skinner C Three cases of "spice" exposure. Clin Toxicol (Phila) 2011, 49(5):431-433.
135. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011, 49(8):760-764.
136. McQuade D, Hudson S, Dargan PI, Wood DM, et al. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 2013, 69(3):373-376.
137. Schwartz MD, et al. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR 2013, 62(6):93-98.
138. Nelms B. Beware of the Spice of death - After teen dies, cops warn about legal 'synthetic marijuana'. 2012 (cited 2013 March 17th); Available: <>. http://www.thecitizen.com/articles/03-14-2012/beware-spice-death-%E2%80%94-after-teen-dies-cops-warn-about-legal-%E2%80%98synthetic-marijuana%E2%80%99.
139. Synthetic Marijuana Memorials. Available: <> [accessed 19.03.13]. http://tothemaximusblog.org/?page_id=560.
140. Tomiyama K, Funada M Drug discrimination properties and cytotoxicity of the cannabinoid receptor ligands. Nihon Arukoru Yakubutsu Igakkai Zasshi 2012, 47(3):135-143.
141. Ginsburg BC, Schulze DR, Hruba L, McMahon LR JWH-018 and JWH-073: Delta(9)-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 2012, 340(1):37-45.
142. Hruba L, Ginsburg BC, McMahon LR Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Delta(9)-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 2012, 342(3):843-849.
143. Ware MA, St Arnaud-Trempe E The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010, 105(3):494-503.
144. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL 'Spice' and 'K2' herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012, 21(4):320-326.
145. Erowid. Products - spice and synthetic cannabinoids reports. Erowid experience vaults Available: <> [accessed 17.04.12]. http://www.erowid.org/experiences/subs/exp_Products_Spice_and_Synthetic_Cannabinoids.shtml#Addiction_&_Habituation.
146. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal phenomena and dependence syndrome after the consumption of 'spice gold'. Dtsch Arztebl Int 2009, 106(27):464-467.
147. Rominger A, Cumming P, Xiong G Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D receptor availability: A (F)fallypride PET study. Eur Neuropsychopharmacol 2013, (Epub ahead of print).
148. Fraser AD, Worth D Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int 2003, 133(1-2):26-31.
149. Johansson E, Halldin MM Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 1989, 13(4):218-223.